Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAF(V600) mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study / Ascierto, P. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 36:15(2018). ( 2018 ASCO Annual Meeting) [10.1200/JCO.2018.36.15_suppl.9522].
Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAF(V600) mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study
Ascierto P
2018
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
